Enanta Pharmaceuticals | ENTA - Процентные расходы





Процентные расходы Изменить Дата
AbbVie USD 688M 58M 2026-09
Amgen USD 653M 94.99B 2026-09
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
AstraZeneca USD 371M 31M 2026-09
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 403M 4M 2026-09
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Gilead Sciences USD 269M 22M 2026-09
GlaxoSmithKline GBP 219M 98M 2026-09
Halozyme Therapeutics USD 6.04M 457K 2026-09
Heron Therapeutics USD 600K 100K 2024-12
Immunic 197K 222K 2025-12
Incyte USD 605K 23K 2026-09
Insmed USD 20.41M 1.57M 2026-09
Ionis Pharmaceuticals USD 18M 1000K 2026-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 525M 46M 2026-06
Neurocrine Biosciences USD 300K 2.6M 2026-09
Novartis USD 468M 6M 2026-09
Novavax USD 5.82M 342K 2025-12
Pfizer USD 662M 5M 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Vertex Pharmaceuticals USD 36M 32.7M 2026-09